NC patients who developed HCC had higher AST levels, FIB-4 scores, ALBI scores, and AFP concentrations and lower ALB levels and PLT counts before DAA treatment than those who did not develop HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.